Vabomere Generic: When Will Generic Meropenem and Vaborbactam Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Vabomere Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? April 2039 About 12.5 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? April 2039 10 patents listed with the FDA
- Can you buy a generic today? Not yet No company lists one for sale
Generic meropenem and vaborbactam is expected to be available in April 2039, about 12.5 years away. None is for sale yet.
Why April 2039?
It is when Vabomere’s patents 11,376,237 and 12,533,342 end. They cover a way of using it, and once they end, generics can go on sale as soon as the FDA approves them. We rate it toss-up: still unsettled. Just as likely to slip as to hold.
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Vabomere as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Vabomere by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Toss-up Still unsettled. Just as likely to slip as to hold.
- Price competition
- None filed yet No filers on record
- Brand sales
- $30M a yearSmaller seller
- FDA approved 2017 August 2017 FDA Orange Book
- Patents listed 10 last runs to April 2039 FDA Orange Book
- Medicare Part D spent $2.4M in 2025, for 138 people CMS Part D Spending by Drug
- Medicaid prescriptions 172 in the last four reported quarters, $468.2K CMS Medicaid drug utilization, to Q1 2026
Vabomere’s Road to a Generic
Vabomere has had the market to itself since the FDA approved it in August 2017 (Rempex Pharmaceuticals Inc A Wholly Owned Sub Of Melinta Therapeutics LLC). Its FDA protection (antibiotic incentive (gain)) runs to August 2027. Its 10 listed patents run to April 2039.
The first generic of Vabomere is expected in April 2039.
Why that month: patents 11,376,237 and 12,533,342, on a way of using it, end then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Vabomere Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Vabomere’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patents 11,376,237 and 12,533,342, which end in April 2039, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 9,694,025 | A way of using it (U-2120) | August 2031 | Active |
| 10,172,874 | The product’s formulation | August 2031 | Active |
| 10,183,034 | A way of using it (U-2490) | August 2031 | Active |
| 10,561,675 | A way of using it (U-2490) | August 2031 | Active |
| 11,007,206 | A way of using it (U-3128) | August 2031 | Active |
| 12,171,772 | The active ingredient | August 2031 | Active |
| 8,680,136 | The active ingredient; the product’s formulation | August 2031 | Active |
| 12,478,606 | A way of using it (U-3421) | January 2038 | Active |
| 11,376,237 Sets the expected month of generic availability | A way of using it (U-3421) | April 2039 | Active |
| 12,533,342 Sets the expected month of generic availability | A way of using it (U-3421) | April 2039 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New chemical entity NCE | Five years of protection for a medicine whose active ingredient the FDA had never approved before. | August 2022 | Ended |
| Antibiotic incentive (GAIN) GAIN | Five more years for a medicine that treats a serious or life-threatening infection. | August 2027 | Active |
Source: FDA Orange Book, application 209776. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Meropenem and Vaborbactam
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Vabomere yet.
Approved by the FDA
Not yet. The FDA has not approved a generic meropenem and vaborbactam. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic meropenem and vaborbactam for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Vabomere Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Vabomere, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Vabomere
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Vabomere, before manufacturer rebates.
- $374.5K
- January to March 2026, the latest CMS has posted
For 30 people, about $3,467 per prescription fill - $2.4M
- 2025, the whole year
For 138 people, about $3,687 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $374,459 | 30 | $3,467.21 |
| 2025 | $2,374,253 | 138 | $3,686.73 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Vabomere only, so no generic is counted in it. What CMS says it is used for: This product is used to treat a variety of bacterial infections. It contains 2 different medications: meropenem and vaborbactam.
Medicaid Prescriptions by Quarter
172 prescriptions in the four quarters to Q1 2026, $468.2K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 32 | $41,853 |
| Q4 2025 | 12 | $89,597 |
| Q3 2025 | 37 | $120,071 |
| Q2 2025 | 91 | $216,697 |
| Q1 2025 | 0 | $0 |
Source: CMS Medicaid State Drug Utilization Data, over Vabomere’s own package codes.
Vabomere Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 1GM/VIAL;1GM/VIAL | Powder | Intravenous | August 2017 | Prescription reference product |
Source: FDA Orange Book, Rempex Pharmaceuticals Inc A Wholly Owned Sub Of Melinta Therapeutics LLC. Listed for sale today by Melinta Therapeutics, LLC (FDA NDC Directory).
Vabomere NDC Codes and Packages
Each Vabomere package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 70842-0120-06 | VABORBACTAM 1 g/2g / MEROPENEM 1 g/2g injection, powder, for solution | carton of 6 vials of 2 g | Melinta Therapeutics, LLC |
| 70842-0120-06 | VABORBACTAM 1 g/2g / MEROPENEM 1 g/2g injection, powder, for solution | carton of 6 vials of 2 g | Melinta Therapeutics, LLC |
Source: the FDA NDC Directory, current listings only. Only packages sold under Vabomere’s own FDA approval (NDA 209776) are listed, never a generic. Some codes belong to companies that repackage Vabomere: it is the same medicine in a different package.
What a Generic Vabomere Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Vabomere as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Vabomere”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Vabomere
Is there a generic for Vabomere right now?
No. As of October 9, 2026 no generic meropenem and vaborbactam is listed for sale in the FDA NDC Directory.
When will Vabomere go generic?
April 2039 is the expected month, and that is toss-up but not certain. It is when Vabomere’s patents 11,376,237 and 12,533,342 end. They cover a way of using it, and once they end, generics can go on sale as soon as the FDA approves them.
Will generic meropenem and vaborbactam be the same as Vabomere?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Vabomere?
Not yet. The FDA Orange Book lists no approved generic version of Vabomere.
When does the Vabomere patent expire?
The FDA Orange Book lists 10 patents for Vabomere; the last runs to April 2039. The one behind the expected month is patents 11,376,237 and 12,533,342, which end in April 2039. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (April 2039) weighs all of that.
Changes to This Projection
- First generic expected April 2039 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- KovanazeOxymetazoline Hydrochloride and Tetracaine HydrochlorideApril 2030
- Otezla XRApremilast2031 to 2032
- SymproicNaldemedine TosylateFebruary 2031
- XcopriCenobamate2035 to 2036
- BeizrayDocetaxelMay 2036
- EvdiTrabectedinFebruary 2043
About Vabomere
- Generic name meropenem and vaborbactam
- How it is taken Into a vein (IV)
- Company Rempex Pharmaceuticals Inc A Wholly Owned Sub Of Melinta Therapeutics LLC
- More drugs Brand-name drugs starting with V
- Have a question? A pharmacist answers, free. Ask about Vabomere
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.